Biological, clinical and population relevance of 95 loci for blood lipids. by Teslovich, Tanya M et al.
UCSF
UC San Francisco Previously Published Works
Title
Biological, clinical and population relevance of 95 loci for blood lipids.
Permalink
https://escholarship.org/uc/item/61w7w636
Journal
Nature, 466(7307)
ISSN
0028-0836
Authors
Teslovich, Tanya M
Musunuru, Kiran
Smith, Albert V
et al.
Publication Date
2010-08-01
DOI
10.1038/nature09270
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Biological, Clinical, and Population Relevance of 95 Loci for 
Blood Lipids
A full list of authors and affiliations appears at the end of the article.
Abstract
Serum concentrations of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), and triglycerides (TG) are among the most important risk 
factors for coronary artery disease (CAD) and are targets for therapeutic intervention. We screened 
the genome for common variants associated with serum lipids in >100,000 individuals of 
European ancestry. Here we report 95 significantly associated loci (P < 5 × 10-8), with 59 showing 
genome-wide significant association with lipid traits for the first time. The newly reported 
associations include single nucleotide polymorphisms (SNPs) near known lipid regulators (e.g., 
CYP7A1, NPC1L1, and SCARB1) as well as in scores of loci not previously implicated in 
lipoprotein metabolism. The 95 loci contribute not only to normal variation in lipid traits but also 
to extreme lipid phenotypes and impact lipid traits in three non-European populations (East 
Asians, South Asians, and African Americans). Our results identify several novel loci associated 
with serum lipids that are also associated with CAD. Finally, we validated three of the novel genes
—GALNT2, PPP1R3B, and TTC39B—with experiments in mouse models. Taken together, our 
findings provide the foundation to develop a broader biological understanding of lipoprotein 
metabolism and to identify new therapeutic opportunities for the prevention of CAD.
Serum concentrations of total cholesterol (TC), low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol, and triglycerides are heritable risk factors for cardiovascular 
disease and targets for therapeutic intervention1. Genome-wide association studies 
(GWASs) involving up to 20,000 individuals of European ancestry have identified >30 
genetic loci contributing to inter-individual variation in serum lipid concentrations2-10. Half 
of these loci harboured genes previously known to influence serum lipid concentrations, 
establishing the technical validity of the lipid GWAS. Nevertheless, the practical value of 
the GWAS approach remains a subject of debate11-14.
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Here we focus on three key questions motivated by recent progress in genetic mapping: (1) 
are loci identified in populations of European descent important in non-European groups, 
suggesting relevance in different global populations; (2) are these loci of clinical relevance, 
providing the framework to identify potential novel drug targets for the treatment of extreme 
lipid phenotypes and prevention of coronary artery disease (CAD); and (3) do these loci 
harbour genes with biological relevance, i.e., are directly involved in lipid regulation and 
metabolism?
We address these questions using several approaches: a genome-wide association screen for 
serum lipids in >100,000 individuals of European ancestry; evaluation of mapped variants in 
East Asians, South Asians, and African Americans; association testing in individuals with 
and without coronary artery disease (CAD); evaluation of genetic variants in patients with 
extreme serum lipid concentrations; and genetic manipulation in mouse models.
Genome-Wide Association Mapping in >100,000 Individuals
To identify additional common variants associated with serum TC, LDL-C, HDL-C, and TG 
concentrations, we performed meta-analysis of 46 lipid GWASs (Supplementary Tables 
1-4). These studies together comprise >100,000 individuals of European descent (maximum 
sample size 100,184 for TC; 95,454 for LDL-C; 99,900 for HDL-C; and 96,598 for TG), 
ascertained in the United States, Europe, or Australia. In each study, we used genotyped 
single nucleotide polymorphisms (SNPs) and phased chromosomes from the HapMap CEU 
(Utah residents with ancestry from northern and western Europe) sample to impute 
autosomal SNPs catalogued in the HapMap; SNPs with minor allele frequency (MAF) >1% 
and good imputation quality (see Methods) were analysed. A total of ∼ 2.6 million directly 
genotyped or imputed SNPs were tested for association with each of the four lipid traits in 
each study. For each SNP, evidence of association was combined across studies using a 
fixed-effects meta-analysis.
We identified 95 loci that showed genome-wide significant association (P < 5 × 10-8) with 
at least one of the four traits tested (Fig. 1; Supplementary Fig. 1; Supplementary Table 2). 
These include all of the 36 loci previously reported by GWAS at genome-wide 
significance2-10 and 59 loci reported here in a GWAS for the first time. Among these 59 
novel loci, 39 demonstrated genome-wide significant association with TC, 22 with LDL-C, 
31 with HDL-C, and 16 with TG. Among the 36 known loci, 21 demonstrated genome-wide 
significant association with another lipid phenotype in addition to that previously described. 
To rule out spurious associations arising as a result of imputation artifact, at nearly all loci 
we were able to identify proxy SNPs that had been directly genotyped on Illumina and/or 
Affymetrix arrays and confirm each of the associations (Supplementary Table 5). The full 
association results for each of the four traits are available at http://
www.broadinstitute.org/mpg/pubs/lipids2010/ or http://www.sph.umich.edu/csg/abecasis/
public/lipids2010.
To evaluate whether additional independent association signals existed at each locus, we 
performed conditional association analyses for each of the four lipid traits including 
genotypes at the lead SNPs for each of the 95 loci as covariates in the association analyses 
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(see Methods). These analyses identified secondary signals in 26 loci (Supplementary Table 
6); when these additional SNPs are combined with the lead SNPs, the total set of mapped 
variants explains 12.4% (TC), 12.2% (LDL-C), 12.1% (HDL-C), and 9.6% (TG) of the total 
variance in each lipid trait in the Framingham Heart Study, corresponding to ∼25-30% of 
the genetic variance for each trait.
Previous studies have suggested sex-specific heritability of lipid traits15. A key challenge in 
addressing this issue is evaluating enough men and women to achieve adequate statistical 
power for each sex. We re-analysed the GWAS for the four lipid traits separately in women 
(n = 63,274) and in men (n = 38,514). Four of the 95 loci identified in the primary analysis 
showed significant heterogeneity of effect size (P < 0.0005) between men and women 
(Supplementary Table 7). Moreover, an additional five loci had significant association in 
only one sex and not in the sex-combined analysis. Two loci associated with HDL-C in the 
sex-combined analysis (KLF14 and ABCA8) showed female-specific association with TG 
and LDL-C, respectively. The KLF14 locus is a striking example, with rs1562398 
significantly associated with TG in women (effect size = −0.046 for the C allele, P = 2 × 
10-12), but not in men (effect size = −0.012, P = 0.05) (Supplementary Fig. 2; 
Supplementary Table 7).
To gain insight into how DNA variants in associated loci might influence serum lipid 
concentrations, we tested whether the mapped DNA sequence variants regulate the 
expression levels of nearby genes (expression quantitative trait loci, or eQTLs) in human 
tissues relevant to lipoprotein metabolism (liver and fat)16. We carried out genotyping and 
RNA expression profiling of >39,000 transcripts in three types of human tissue samples 
from: liver (960 samples), omental fat (741 samples), and subcutaneous fat (609 samples). 
We examined the correlations between each of the lead SNPs at the 95 loci and the 
expression levels of transcripts located within 500 kb of the SNP. We pre-specified a 
conservative threshold of statistical significance at P < 5 × 10-8. At this threshold, we 
identified 38 SNP-to-gene eQTLs in liver, 28 in omental fat, and 19 in subcutaneous fat 
(Fig. 1 ; Supplementary Tables 8-10). Some lead SNPs are quite remote from the associated 
gene transcripts. For example, rs9987289 (associated with both LDL-C and HDL-C) 
correlates with a two-fold change in liver expression of PPP1R3B, yet is 174 kb away from 
the gene, which as demonstrated below is likely to be a causal gene. Similarly, rs2972146 
(associated with both HDL-C and TG in this study, as well as with insulin resistance and 
type 2 diabetes mellitus in a prior study17) correlates with IRS1 expression in omental fat, 
despite being located 495 kb away from the gene.
Relevance of GWAS Loci in Non-Europeans
As all of the individuals studied in our primary GWAS were of European ancestry, it 
remained unclear if the loci we identified in Europeans are relevant in non-European 
individuals. To address this question, we performed additional analyses in cohorts 
comprising >15,000 East Asians (Chinese, Koreans, and Filipinos), >9,000 South Asians, 
and >8,000 African Americans (Fig. 1; Supplementary Table 11). As a similarly sized 
control, we also performed genotyping in a cohort of 7,000 additional Europeans.
Teslovich et al. Page 3
Nature. Author manuscript; available in PMC 2011 February 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
In the European group, we found that 35 of 36 lead SNPs tested against LDL-C had the 
same direction of association as seen in the primary (>100,000 person) analysis (see 
Supplementary Table 12 for explanation); 44 of 47 SNPs for HDL-C; and 29 of 32 SNPs for 
TG. Such directional consistency for the three traits is unlikely to be due to chance (P = 5 × 
10-10 for LDL-C; P = 1 × 10-10 for HDL-C; and P = 1 × 10-6 for TG). For further replication 
evidence, we performed direct genotyping of a subset of the lead SNPs in two European 
cohorts together totalling 12,000 individuals and found that 24 of 26 tested SNPs had the 
same direction of association (Supplementary Table 13).
We observed similar proportions in South Asians, with 29 of 32 lead SNPs tested against 
LDL-C having the same direction of association as in the primary analysis (P = 1 × 10-6); 35 
of 39 SNPs for HDL-C (P = 2 × 10-7); and 24 of 27 SNPs for TG (P = 3 × 10-5). We also 
had consistent results with East Asians [LDL-C: 29 of 36, P = 2 × 10-4; HDL-C: 38 of 44, P 
= 5 × 10-7; TG: 26 of 28, P = 2 × 10-6], with more modest evidence for replication in 
African Americans [LDL-C: 33 of 36, P = 1 × 10-7; HDL-C: 37 of 44, P = 3 × 10-6; TG: 24 
of 30, P = 7 × 10-4]. Furthermore, we found that the proportions of SNPs that had the same 
direction of association and P < 0.05 were similar in the European, South Asian, and East 
Asian replication groups, with smaller proportions in African Americans (Supplementary 
Table 12). Of note, for a majority of the loci, there was no evidence of heterogeneity of 
effects between the primary European groups and each of the non-European groups 
(Supplementary Table 11).
These observations suggest that most (but likely not all) of the 95 lipid loci identified in this 
study contribute to the genetic architecture of lipid traits widely across global populations. 
They also suggest future studies to localize causal DNA variants by leveraging differences 
in linkage disequilibrium (LD) patterns among populations. We evaluated the potential for 
fine mapping by comparing the number of SNPs in LD with lead SNPs in three HapMap 
populations (Supplementary Table 14). At many loci, only a subset of SNPs in high LD (r2 
≥ 0.8) with the lead SNP in HapMap CEU are also in high LD with the lead SNP in HapMap 
YRI (Yoruba in Ibadan, Nigeria) individuals or in the joint JPT+CHB (Japanese in Tokyo, 
Japan and Han Chinese in Beijing, China) cohort. Such differential LD patterns can prove 
useful to refine association boundaries and prioritize SNPs for functional evaluation, as 
demonstrated for the LDL-C-associated locus on chromosome 1p13 (reported in a separate 
study in this issue of Nature18).
Clinical Relevance of GWAS Loci
To assess whether the GWAS approach yields clinical insights of potential therapeutic 
relevance, we sought to determine which of the lipid-associated lead SNPs are also 
associated with CAD in a manner consistent with established epidemiological relationships 
(i.e., SNP alleles which increase TC, LDL-C, or TG or that decrease HDL-C should be 
associated with increased risk of CAD). Whereas LDL-C is an accepted causal risk factor 
for CAD, it is unclear whether HDL-C and/or TG are also causal risk factors. This 
uncertainty was reinforced by the failure of a drug that raised HDL-C via CETP inhibition to 
reduce the risk of cardiovascular disease19.
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Whether other drugs that specifically raise HDL-C or lower TG can reduce CAD risk 
remains an open question. In contrast, the most widely marketed drugs for lowering of LDL-
C, statins, have been demonstrated in numerous clinical trials to reduce risk of CAD. Statins 
inhibit hydroxy-3-methylglutaryl coenzyme A reductase (the protein product of HMGCR) 
and thereby reduce LDL-C and TC levels. We observed that the variant of our lead SNP in 
the HMGCR locus that is associated with lower LDL-C levels is also associated with lower 
CAD risk (P = 0.004), consistent with the clinical effects of statins. Analogously, common 
variants in other lipid-associated loci that are also associated with CAD may implicate genes 
at these loci as possible therapeutic targets.
We performed association testing for each of the lead SNPs from this study in 24,607 
individuals of European descent with CAD and 66,197 without CAD, with a pre-specified 
one-sided significance threshold of P < 0.001 requiring directionality consistent with the 
relevant lipid-CAD epidemiological relationship. A limited number of loci met this criterion 
(Fig. 1; Supplementary Table 15), with most of them being associated with LDL-C—
consistent with LDL-C being a causal risk factor for CAD.
Four novel CAD-associated loci related specifically to HDL-C or TG but not LDL-C: IRS1 
(HDL-C, TG), C6orf106 (HDL-C), KLF14 (HDL-C), and NAT2 (TG). That these loci were 
associated with CAD suggests that there may be selective mechanisms by which HDL-C or 
TG can be altered in ways that also modulate CAD risk. However, it is also possible that 
causal genes in these loci may have pleiotropic effects on non-lipid parameters that are 
causal for CAD risk reduction. For example, the major allele of the lead SNP in the IRS1 
locus is associated with increased risk of type 2 diabetes mellitus, insulin resistance, and 
hyperinsulinemia17, along with decreased HDL-C, increased TG, and increased risk of 
CAD; it remains unclear which of the metabolic risk factors are responsible for the increased 
CAD risk.
Besides CAD, a second clinically relevant phenotype is hyperlipidemia. We asked whether 
the common variants in the 95 associated loci, each with individually small effects on serum 
lipids, combine to contribute to extreme lipid phenotypes. We genotyped individuals 
identified in three independent studies as having high LDL-C (n = 532, mean 219 mg/dL), 
high HDL-C (n = 652, mean 90 mg/dL), or high TG (n = 344, mean 1,079 mg/dL). For each 
extreme case group, individuals with low serum LDL-C (n = 532, mean 110 mg/dL), HDL-
C (n = 784, mean 36.2 mg/dL), or TG (n = 144, mean 106 mg/dL) served as control groups. 
In each case-control sample set, we calculated risk scores summarizing the number of LDL-
C-, HDL-C-, or TG-raising alleles weighted by effect size.
For LDL-C, we found that individuals with LDL-C allelic dosage score in the top quartile 
were 13 times as likely to have high LDL-C than individuals in the bottom quartile (P = 1 × 
10-14) (Supplementary Fig. 3; Supplementary Tables 16, 17). For HDL-C, individuals in the 
top quartile of HDL-C risk score were four times as likely to have high HDL-C than 
individuals in the bottom quartile (P = 2 × 10-16). For TG, individuals in the top quartile of 
TG risk score were 44 times as likely to be hypertriglyceridemic than individuals in the 
bottom quartile (P = 4 × 10-28). These results suggest that the additive effects of multiple 
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common variants contribute to determining membership in the extremes of a quantitative 
trait distribution.
Biological Relevance of GWAS Loci
Whether the GWAS approach can yield biological insights that improve our understanding 
of the mechanisms underlying phenotypes such as serum lipid concentrations remains an 
open question. Loci identified through GWAS may explain a very small proportion of the 
variance in a phenotype through naturally occurring common variants in humans, but they 
may have a greater impact through rare variants or when targeted by pharmacological or 
genetic intervention.
We surveyed our 95 GWAS loci and asked whether any nearby genes are linked to known 
Mendelian lipid disorders. There is remarkable overlap between the loci identified here and 
18 genes previously implicated in Mendelian lipid disorders (Supplementary Table 18). 
Fifteen of the genes underlying these Mendelian disorders lie within 100 kb of one of our 
lead SNPs, including 8 that lie within 10 kb of the nearest lead SNP. In 1,000,000 
simulations of 95 randomly drawn SNPs, selected to match our lead SNPs with respect to 
MAF and the number of nearby genes, the average simulation showed no overlapping loci 
and none showed >8 overlapping loci.
An additional two loci represent well-established drug targets for the treatment of 
hyperlipidemia: HMGCR (statins) and NPC1L1 (ezetimibe). Several other loci harbor genes 
already appreciated to influence lipid metabolism prior to this study: LPA, which encodes 
lipoprotein(a); PLTP, which encodes phospholipid transfer protein; ANGPTL3 and 
ANGPTL4, lipoprotein lipase inhibitors; SCARB1, a HDL receptor which mediates selective 
uptake of cholesteryl ester; CYP7A1, which encodes cholesterol 7-alpha-hydroxylase; 
STARD3, a cholesterol transport gene; and LRP1 and LRP4, members of the LDL receptor-
related protein family. Notably, the protein product of one of the genes implicated by our 
study—MYLIP—is a ubiquitin ligase that had no recognized role in lipid metabolism prior 
to our study's inception, but has since been independently demonstrated to be a regulator of 
cellular LDL receptor levels and is now termed Idol (inducible degrader of the LDL 
receptor)20.
GALNT2 (encoding UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 2) is a member of a family of GalNAc-transferases, which 
transfer an N-acetyl galactosamine to the hydroxyl group of a serine/threonine residue in the 
first step of O-linked oligosaccharide biosynthesis. It is the only gene in the mapped locus 
on chromosome 1q42 within 150 kb of the lead SNP (rs4846914), which is located in an 
intron of the gene. We therefore reasoned that GALNT2 would be an ideal candidate for 
functional validation in a mouse model. We introduced the mouse orthologue Galnt2 into 
mouse liver via a viral vector. Liver-specific overexpression of Galnt2 resulted in 
significantly lower plasma HDL-C (24% compared to control mice) by 4 weeks (Fig. 2a). 
We also performed knockdown of endogenous liver Galnt2 through delivery of an shRNA 
via a viral vector. Reduction of the transcript level (∼95% knockdown as determined by 
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qRT-PCR) resulted in higher HDL-C levels by 4 weeks (71% compared to control mice) 
(Fig. 2b). These observations validate GALNT2 as a biological mediator of HDL-C levels.
We further asked whether eQTL studies could facilitate the identification of causal genes in 
loci with multiple genes. Out of several genes surrounding a locus on chromosome 8p23 
found to be associated with HDL-C, LDL-C, and TC (Fig. 1), only PPP1R3B [encoding 
protein phosphatase 1, regulatory (inhibitor) subunit 3B] was found to have an eQTL in liver 
(Supplementary Table 7). The allele associated with increased expression correlated with 
lower levels of each of the lipid traits. This eQTL relationship suggests that higher 
expression of PPP1R3B will lower plasma lipids. Consistent with this prediction, 
overexpression of the mouse orthologue Ppp1r3b in mouse liver via a viral vector resulted 
in significantly lower plasma HDL-C levels at two weeks (25%) and four weeks (18%) (Fig. 
2c), as well as lower TC levels at two weeks (21%) and four weeks (14%) (data not shown).
Similarly, on a locus on chromosome 9p22 found to be associated with HDL-C, TTC39B 
(encoding tetratricopeptide repeat domain 39B) was the only one of several genes in the 
locus to exhibit an eQTL in liver (Supplementary Table 7), with the allele associated with 
decreased expression correlating with increased HDL-C. Consistent with this eQTL, 
knockdown of the mouse orthologue Ttc39b via a viral vector, with 50% knockdown of 
transcript as determined by qRT-PCR, resulted in significantly higher plasma HDL-C levels 
at four days (19%) and seven days (14%) (Fig. 2d). These data suggest PPP1R3B and 
TTC39B as causal genes for lipid regulation. These findings, combined with the 
demonstration that SORT1 is a causal gene for LDL-C and is regulated in its expression by a 
GWAS SNP (reported in a separate study in this issue of Nature18), support the use of eQTL 
studies to prioritize functional validation of GWAS-nominated genes.
Together, these observations establish that some of the identified 95 loci harbour novel bona 
fide lipid regulatory genes and suggest that with additional functional studies many, if not 
all, of the loci will yield insights into the biological underpinnings of lipid metabolism.
New Biological, Clinical, and Genetic Insights
Through a series of studies, we demonstrate that (1) at least 95 loci across the human 
genome harbour common variants associated with serum lipid traits in Europeans; (2) the 
loci contribute to lipid traits in multiple non-European populations; (3) some of these loci 
are associated not only with lipids but also with risk for CAD; (4) common variants in the 
loci combine to contribute to extreme lipid phenotypes; and (5) many of the identified loci 
harbour genes that contribute to lipid metabolism, including the novel lipid genes GALNT2, 
PPP1R3B, and TTC39B that we validated in mouse models.
It has recently been suggested that conducting genetic studies with increasingly larger 
cohorts will be relatively uninformative for the biology of complex human disease, 
particularly if initial studies have failed to explain a sizable fraction of the heritability of the 
disease in question.11 As the reasoning goes, analysis of a few thousand individuals will 
uncover the common variants with the strongest effect on phenotype. Larger studies will 
suffer from a plateau phenomenon in which either no additional common variants will be 
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found or any common variants that are identified will have too small an effect to be of 
biological interest.
Our study provides strong empirical evidence against this assertion. We extended a GWAS 
for serum lipids from ∼20,000 to ∼100,000 individuals and identified 95 loci (of which 59 
are novel) that, in aggregate, explain 10%-12% of the total variance (representing ∼25-30% 
of the genetic variance). Even though the lipid-associated SNPs we identified have relatively 
small effect sizes, some of the 59 new loci contain genes of clear biological and clinical 
importance—among them LDLRAP1 (responsible for autosomal recessive 
hypercholesterolemia), SCARB1 (receptor for selective uptake of HDL-C), NPC1L1 
(established drug target), MYLIP (recently characterized regulator of LDL-C), and 
PPP1R3B (newly characterized regulator of HDL-C). We expect that future investigations 
of the new loci (e.g., resequencing efforts to identify low-frequency and rare variants, or 
functional experiments in cells and animal models, as demonstrated for SORT1 in a separate 
study reported in this issue of Nature18) will uncover additional important new genes. Thus, 
the data presented in this study provide a foundation from which to develop a broader 
biological understanding of lipoprotein metabolism and to identify potential new therapeutic 
opportunities.
Methods Summary
The full Methods are in Supplementary Information and provide information about: (1) 
study samples and phenotypes; (2) genotyping and imputation; (3) genome-wide association 
analyses; (4) meta-analyses of directly typed and imputed SNPs; (5) estimation of effect 
sizes; (6) conditional analyses of top signals; (7) sex-specific analyses; (8) cis-expression 
quantitative trait locus analyses; (9) analyses of lipid-associated SNPs in European and non-
European samples; (10) analyses of lipid-associated SNPs in individuals with and without 
CAD; (11) analyses of associated SNPs in patients with extreme LDL-C, HDL-C, or TG 
levels; (12) simulation studies to assess overlap between GWAS signals and Mendelian 
disease loci; and (13) details of mouse studies.
Supplementary Material
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Figure 1. Meta-analysis of plasma lipid concentrations in >100,000 individuals of European 
descent
The gene name listed in “Locus” column is either a plausible biological candidate gene in 
the locus or the nearest annotated gene to the lead SNP. Listed in “Lead Trait” column is the 
lipid trait with best P-value among all four traits. Listed in “Other Traits” are additional lipid 
traits with P < 5 × 10-8. Listed in “Alleles/MAF” column are: major allele, minor allele, and 
minor allele frequency (MAF) within the combined cohorts included in this meta-analysis 
(alleles designated with respect to the “+” strand; Supplementary Table 2). Numbers in 
“Effect Size” column are in mg/dL for the lead trait, modeled as an additive effect of the 
minor allele. P-values are listed for the lead traits. In the “eQTL” column, “Y” indicates that 
lead SNP has an eQTL with at least one gene within 500 kb with P < 5 × 10-8 in at least one 
the three tissues tested (liver, omental fat, subcutaneous fat). In the “CAD” column, “Y” 
indicates that the lead SNP meets the pre-specified statistical significance threshold of P < 
0.001 for association with CAD and being concordant between the direction of lipid effect 
and the change in CAD risk. In the “Ethnic” column, “+” indicates concordant effect on lead 
trait of the variant between the primary meta-analysis cohort and the European or non-
European group, “−” indicates discordant effect on lead trait, and “?” indicates data not 
available for the group; in order, the ethnic groups are European, East Asian, South Asian, 
and African American (Supplementary Table 11).
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Figure 2. Effects of altered Galnt2, Ppp1r3b, or Ttc39b expression in mouse liver on plasma lipid 
levels
a, b, Overexpression and knockdown of Galnt2. Shown are plasma HDL-C levels at 
baseline, 2 weeks, or 4 weeks after injection of viral vectors. n = 6 mice per group. c, 
Overexpression of Ppp1r3b. Shown are plasma HDL-C levels at baseline, 2 weeks, or 4 
weeks after injection of viral vectors. n = 7 mice per group. d, Knockdown of Ttc39b. 
Shown are plasma HDL-C levels at baseline, 4 days, or 7 days after injection of viral 
vectors. n = 6 mice per group. Error bars show standard deviations. Because independent 
experiments were performed at different times and/or sites, there is variability in baseline 
HDL-C levels.
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